# Healthcare Economist * **Definition:** Healthcare Economist is a blog and online platform that provides analysis, commentary, and insights on health economics, healthcare policy, and the economics of healthcare systems, aimed at professionals, researchers, and policymakers in the healthcare sector. * **Taxonomy:** Key Sources / Healthcare Publications / Healthcare Economist ## News * Selected news from the source **Healthcare Economist**, for healthcare technology leaders * 167 news items are in the system for this source * Posts have been filtered for tech-related keywords | Date | Title | Topics | | --- | --- | --- | | 3/13/2025 | [**What is the Critical Medicines Act?**](https://www.healthcare-economist.com/2025/03/13/what-is-the-critical-medicines-act/) | [[Pharma]]; [[Health]]; [[Strategy]] | | 2/11/2025 | [**How long until widespread AI use comes to health systems?**](https://www.healthcare-economist.com/2025/02/11/how-long-until-widespread-ai-use-comes-to-health-systems/) | [[Patient Experience]]; [[Smart Medical Devices]]; [[FDA Approvals]] | | 2/6/2025 | [**What will be DOGE's impact on CMS?**](https://www.healthcare-economist.com/2025/02/06/what-will-be-doges-impact-on-cms/) | [[Audit]]; [[Healthcare Providers]]; [[Health]] | | 1/27/2025 | [**Will the Medicare Drug Price Negotiation increase innovation?**](https://www.healthcare-economist.com/2025/01/27/will-the-medicare-drug-price-negotiation-increase-innovation/) | [[Medicaid]]; [[Healthcare Accessibility]]; [[Rural Healthcare Access]] | | 11/25/2024 | [**What is HEMA?**](https://www.healthcare-economist.com/2024/11/25/what-is-hema/) | [[Healthcare Supply Chain]]; [[Technical Assessment]]; [[Healthcare Communications]] | | 11/17/2024 | [**Health care in Spain**](https://www.healthcare-economist.com/2024/11/17/health-care-in-spain/) | [[Hospitals]]; [[Healthcare Costs]]; [[Healthcare Education]] | | 11/4/2024 | [**Should Dynamic Drug Pricing be Incorporated into Cost-Effectiveness Analyses?**](https://www.healthcare-economist.com/2024/11/04/should-dynamic-drug-pricing-be-incorporated-into-cost-effectiveness-analyses/) | [[Health]] | | 10/21/2024 | [**The Future of Medicare's Coverage with Evidence Development Policy**](https://www.healthcare-economist.com/2024/10/21/the-future-of-medicares-coverage-with-evidence-development-policy/) | | | 10/15/2024 | [**FTC erects additional administrative barriers to hospital mergers**](https://www.healthcare-economist.com/2024/10/15/ftc-erects-additional-administrative-barriers-to-hospital-mergers/) | [[Healthcare]]; [[Mergers]]; [[AI in Healthcare]] | | 10/8/2024 | [**Do wait times for breast cancer surgery in the UK vary by socioeconomic status?**](https://www.healthcare-economist.com/2024/10/07/do-wait-times-for-breast-cancer-surgery-in-the-uk-vary-by-socioeconomic-status/) | [[Healthcare Access]] | | 9/26/2024 | [**What are the new CMS Star Ratings Measures for 2025?**](https://www.healthcare-economist.com/2024/09/26/what-are-the-new-cms-star-ratings-measures-for-2025/) | [[Healthcare APIs]]; [[Medicare]]; [[Patient Safety Risks]] | | 9/24/2024 | [**Why aren't alternative payment models working?**](https://www.healthcare-economist.com/2024/09/24/why-arent-alternative-payment-models-working/) | [[Patient Monitoring]]; [[Healthcare Supply Chain]]; [[Risk Analysis]] | | 9/16/2024 | [**Why is the market design for innovative pharmaceuticals not well understood?**](https://www.healthcare-economist.com/2024/09/16/why-is-the-market-design-for-innovative-pharmaceuticals-not-well-understood/) | [[Healthcare Costs]]; [[Drug Development]]; [[Innovation]] | | 9/10/2024 | [**How long does it take new medical research to be adopted by real-world physicians?**](https://www.healthcare-economist.com/2024/09/10/how-long-does-it-take-new-medical-research-to-be-adopted-by-real-world-physicians/) | [[Medical Research]]; [[Medical Innovation]] | | 8/30/2024 | [**How will the FTC law banning noncompete clauses impact physicians?**](https://www.healthcare-economist.com/2024/08/30/how-will-the-ftc-law-banning-noncompete-clauses-impact-physicians/) | [[Patient Safety]]; [[Hospitals]]; [[AI for Healthcare Providers]] | | 8/28/2024 | [**Value Assessment Approaches for Duchenne Muscular Dystrophy Therapies**](https://www.healthcare-economist.com/2024/08/28/value-assessment-approaches-for-duchenne-muscular-dystrophy-therapies/) | [[Neuromuscular Medicine]]; [[Health]]; [[Pharma]] | | 8/26/2024 | [**How to use the RE-AIM framework to evaluate public health interventions**](https://www.healthcare-economist.com/2024/08/26/how-to-use-the-re-aim-framework-to-evaluate-public-health-interventions/) | [[Public Health]]; [[Culture]]; [[Sustainability]] | | 8/15/2024 | [**Medicare Drug Price Negotiation leads to 38% to 79% price decrease**](https://www.healthcare-economist.com/2024/08/15/medicare-drug-price-negotiation-leads-to-38-to-79-price-decrease/) | [[Negotiation]]; [[Medicare]]; [[Drug Price Negotiation]] | | 8/14/2024 | [**Walk-in behavioral health crisis stabilization services reduce ED visits**](https://www.healthcare-economist.com/2024/08/13/walk-in-behavioral-health-crisis-stabilization-services-reduce-ed-visits/) | [[Mental Health Crisis]]; [[Healthcare Real Estate]]; [[Behavioral Health]] | | 8/14/2024 | [**How to fast track approval and reimbursement of innovative medicines**](https://www.healthcare-economist.com/2024/08/14/how-to-fast-track-approval-and-reimbursement-of-innovative-medicines/) | [[Regulatory Affairs]]; [[Clinical Trials]]; [[Virtual Clinical Trials]] | | 8/12/2024 | [**Medical bill shock and imperfect moral hazard**](https://www.healthcare-economist.com/2024/08/12/medical-bill-shock-and-imperfect-moral-hazard/) | [[Hospitals]]; [[Health]] | | 8/4/2024 | [**Are drug prices too high or too low?**](https://www.healthcare-economist.com/2024/08/04/are-drug-prices-too-high-or-too-low/) | [[Innovation]]; [[Pharma]]; [[Drug Development]] | | 7/17/2024 | [**Requiem for odds ratios?**](https://www.healthcare-economist.com/2024/07/17/requiem-for-odds-ratios/) | [[Hospitals]] | | 7/16/2024 | [**IVI is now the “Center for Innovation and Value Research”**](https://www.healthcare-economist.com/2024/07/16/ivi-is-now-the-center-for-innovation-and-value-research/) | [[Innovation]]; [[Technical Assessment]]; [[Healthcare SaaS]] | | 7/1/2024 | [**HTA and cell and gene therapy**](https://www.healthcare-economist.com/2024/07/01/hta-and-cell-and-gene-therapy/) | [[Gene Therapies]]; [[Health]] | ## Recent Stories (Some LLM-derived content — please confirm with above primary sources) ### Topics Covered - **Health Technology Assessment**: Drummond et al. (2023) analyze how HTA bodies evaluate cell and gene therapies in Europe, finding limited inclusion of broader societal value elements. - **Innovation and Value Initiative**: Jason Spangler supports the IVI Center for Innovation & Value Research, emphasizing its mission to advance patient-centered HTA. - **Logistic Regression Reporting**: Health Services Research mandates reporting marginal effects instead of odds ratios for clearer insights into variable impacts. - **Pharmaceutical Pricing**: Tyler Cowen discusses the elasticity of drug supply and its implications for pricing strategies and innovation. - **Cost Sharing Mechanisms**: Anderson et al. (2024) study the effects of medical billing delays on consumer spending decisions. - **Behavioral Health Crisis Care**: Burns et al. (2024) find that BHCC facilities correlate with reduced ED visits for mental health crises. - **Innovative Medicines Regulation**: Ollendorf et al. (2024) recommend clearer criteria for expedited regulatory approval of innovative medicines. - **Medicare Drug Price Negotiation**: CMS establishes maximum fair prices for drugs, with negotiations resulting in significant discounts. - **RE-AIM Framework**: The framework evaluates health promotion programs based on reach, effectiveness, adoption, implementation, and maintenance. - **Value Assessment for DMD Therapies**: Stakeholders call for broader frameworks beyond QALY for evaluating therapies for Duchenne muscular dystrophy. - **FTC Noncompete Clause Rule**: The FTC's new rule significantly restricts noncompete clauses for physicians, aiming to reduce healthcare costs. - **Adoption of Medical Innovations**: DiCicca et al. (2024) find rapid adoption of new evidence in clinical practices, particularly among younger physicians. - **Pharmaceutical Pricing Complexity**: Olivenca et al. (2024) critique the simplistic views on drug pricing, advocating for a market design perspective. - **Alternative Payment Models**: Patel et al. highlight failures in current APMs and suggest improvements for better patient outcomes. - **CMS Star Ratings**: New quality measures for 2025 will influence Medicare Advantage plan evaluations and payments. - **Inequalities in Cancer Surgery Wait Times**: Matias et al. (2024) analyze socioeconomic disparities in waiting times for breast cancer surgery in England. - **FTC Premerger Reporting Requirements**: The FTC updates premerger reporting for healthcare providers, increasing documentation burdens. - **Coverage with Evidence Development**: A panel at USC discusses the intersection of healthcare policy and evidence development in coverage decisions. - **Cost-Effectiveness Analyses**: Whittington et al. (2024) emphasize the need for dynamic pricing in CEAs to accurately reflect drug value. - **Paroxysmal Nocturnal Hemoglobinuria**: A study finds significant complications in PNH patients despite treatment, highlighting unmet medical needs. ### Organizations Mentioned - **Innovation and Value Initiative (IVI)**: A center focused on advancing patient-centered health technology assessment. - **Centers for Medicare & Medicaid Services (CMS)**: A federal agency overseeing Medicare and Medicaid programs, including drug price negotiations. - **Health Services Research**: A journal mandating new reporting standards for logistic regression studies. - **Federal Trade Commission (FTC)**: A government agency regulating competition and consumer protection, recently revising noncompete clause rules. - **American Hospital Association (AHA)**: An organization representing hospitals and healthcare providers, critical of FTC's new reporting requirements. - **USC Schaeffer Center**: An academic center hosting discussions on healthcare policy and evidence development. - **International Society for Pharmacoeconomics and Outcomes Research**: An organization providing frameworks for value assessments in healthcare technologies.